spacer
home > ebr > Autumn 2005
PUBLICATIONS

European Biopharmaceutical Review

ebr
Autumn 2005
At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EBR provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of of biopharmaceuticals, take a look below at the range of articles featured in this issue of EBR.
   
Text
PDF
In the Editor's Letter, Dr Helen Tayton-Martin introduces the articles in this issue  
download pdf
BioBusiness, Finance & Communication
G Steven Burrill, CEO of Burrill & Company, considers the latest deal-making trends, in The Pendulum Swings towards M&As and Partnering for Biotechs  
download pdf
In Accessing Innovation: The Role of Equity Investments in Pharmaceutical R&D and Licensing Agreements, Andrea Elliot-Smith, Business Analyst at Pharmaventures, examines an important component of pharma-biotech collaborations  
download pdf
Universities are situated at the crossroads of research, education and innovation, but is their potential limited by poor links between academia and industry? Ben Rapinoja, Attorney-at-Law and Aura Soininen, LLM at Borenius & Kemppinen Ltd, discuss the possibilities, in University-Industry Collaboration and Technology Transfer  
download pdf
Olivia Lindau-Jonsson, Project Co-ordinator at Business Region Göteborg, suggests that consolidation might be the only way for biotech companies to gain access to financing, strengthen liquidity and survive in a global environment, in Can University Initiatives Influence the M&A Trend in the Biotech Industry?  
download pdf
Science and Innovation
The realisation of large-scale proteomics for drug discovery and proteome mapping will require a solution for the full automation of the bioinformatics pipeline, assert Andrew Dowsey and Guang-Zhong Yang at the Royal Society/Wolfson MIC Laboratory, Imperial College London, in The Road to High-Throughput Proteomics  
download pdf
In Pharmacogenomics in Medical R&D - Catching up with Great Expectations, Dr Duncan McHale, European Head of Clinical Pharmacogenomics at Pfizer Global Research and Development, argues that, while initial hopes have been tempered, optimism remains  
download pdf
Professor Dr Hans-Georg Frank, CSO and Dr Udo Haberl, Head of Drug Design at AplaGen GmbH, predict future improvements on an established therapy, in Treatment of Anaemia - Erythropoietins and Beyond  
download pdf
Delivery by needle may one day be a practice of the past, according to Dr Rocky Cranenburgh, Molecular Genetics Team Leader at Cobra. Discover why in Advances in Recombinant Vaccine Delivery: Live Bacterial Vectors  
download pdf
BioDiscovery
Will the amalgamation of individually limited approaches create a new holistic model? Pieter Muntendam, Managing Director and President at BG Medicine believes so, in Integrating Approaches to Biomarker Development - Transcriptomic, Proteomic, Metabolomic - in Drug Discovery  
download pdf
In Nature's Catalysts and their Applications in the Pharmaceutical Industry, Jenny Littlechild, Professor of Biological Chemistry and Director of the Biocatalysis Centre at the University of Exeter, explores the utility of enzymes found in micro-organisms and seaweeds  
download pdf
Willi Hunziker, CEO of Frimorfo, investigates strategies to reduce difficulties in target selection, in Drowning in Numbers or Hitting Targets? Gene Pool Validation for Refined Drug Development  
download pdf
Paul Lang, Head of the Cellular Pharmacology Group, Dominique Besson, Head of HTS, and Alexander Scheer, Head of the Molecular Screening and Cellular Pharmacology Department at the Serono Pharmaceutical Research Institute, examine approaches to HTS, in Evolution not Revolution - Adopting the High-Throughput Screening Philosophy  
download pdf
BioDevelopment
Further commitment is needed to tackle 'neglected' diseases in developing countries, assert Dr Gerald Dunstan, Principal, and Dr Caroline Wright, Research Analyst, Healthcare & Life Sciences Consulting Practice at Cambridge Consultants, in Development of Biological Therapies for Orphan Indications  
download pdf
Dr Yvonne Perrie, Lecturer in Pharmaceutics/Drug Delivery at Aston Pharmacy School, Aston University, Birmingham, UK, assesses the advantages of Liposome Delivery of Sparingly Soluble Drugs  
download pdf
Regional and international networks increase co-operation and enhance research and development, contends Dr Kate Rowley, Knowledge Transfer Officer at the Scottish Association for Marine Science, Dunstaffnage Marine Laboratory, in Casting Nets to Catch Solutions - New Initiatives in Marine Biotechnology  
download pdf
Dr Paul Lloyd-Evans, Development Scientist for Clinical Biotechnology Centre and Keith Williams, Operations Manager at the Clinical Biotechnology Centre, highlight issues associated with the development of orphan therapies, in Bench to Bedside - A Case Study of the Technology Transfer of a Biopharmaceutical from the Research Laboratory into GMP for Clinical Trials  
download pdf
BioManufacturing
A guide to successful navigation of the intellectual property path is provided in Biomanufacturing: Patent Issues and IP Strategy throughout the Product Life Cycle, by Lorna Brazell, Partner at Bird & Bird  
download pdf
In Search of a Flexible Formatted Tool: Should Disposables be the Golden Rule? Edwin H Schwander, Field Business Development Manager at Nunc A/S, reasons on the unexploited potential of disposables for mass production  
download pdf
Michel HM Eppink, Director DSP Methodology and Troubleshooting, Diosynth Biotechnology Europe, probes Platform Technology for Developing Purification Processes  
download pdf
Dr Maren Topf-Schleuning, Head of Business Development at berlinbiotechpark, asks whether the current equilibrium between supply and demand is set to vanish, in Biomanufacturing Capacity - Bottleneck for the Evolving Biotechnology Industry?  
download pdf
bullet
Preview
In Search of Deal Data: Taking a Look at PartneringreviewTM - Annual Review 2004 - Dr Helen Tayton-Martin, Corporate Development Officer, Allevia AG and Advisory Editor, European Biopharmaceutical Review, sizes up the statistics  
download pdf
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October

News and Press Releases

Bigneat is awarded the Queen’s Award by Lord-Lieutenant of Hampshire

Bigneat Ltd, winner of a Queen’s Award for Enterprise earlier this year, received their Award from Nigel Atkinson Esq, HM Lord-Lieutenant of Hampshire on 16th October at the Bigneat factory in Waterlooville.
More info >>

White Papers

Clinical Trials in Ukraine: Orange Paper Overview and 1st Half Year 2014

Synergy Research Group

The Orange Paper is an analytical report about the clinical trials market in Russia, published quarterly by the contract research organization Synergy Research Group. The first edition of Orange Paper was released in 2006, and at the moment 31 issues have already published. Now, thanks to Synergy Group Ukraine, obtaining information about the market of clinical trials in Ukraine has become possible. In Ukraine, during the period from 1996 to 2013, applicants had obtained 3,864 positive conclusions about the possibility of conducting clinical trials of drugs, both for domestic and foreign manufacturers, including conduct of multinational multi-center clinical trials (hereinafter – MMCTs)
More info >>

Industry Events

3D Cell Culture 2018

21-22 February 2018, Holiday Inn Kensington Forum, London UK

Building on the sell-out success of the launch event, SMi Group is delighted to announce the return of 3D Cell Culture, taking place on 21st and 22nd of February 2018, in London UK.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement